Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study-Reference-Cited by-同舟云学术

Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study

Published:2022-01-13 Issue:4 Volume:107 Page:996-999
ISSN:1592-8721
Container-title:Haematologica
language:
Short-container-title:haematol

Author:

Cerrano Marco,Bonifacio Massimiliano,Olivi Matteo,Curti Antonio,Malagola Michele,Dargenio Michelina,Scattolin Anna Maria,Papayannidis Cristina,Forghieri Fabio,Gurrieri Carmela,Tanasi Ilaria,Zappasodi Patrizia,La Starza Roberta,Fracchiolla Nicola Stefano,Chiusolo Patrizia,Giaccone Luisa,Del Principe Maria Ilaria,Giglio Fabio,Defina Marzia,Favre Claudio,Rizzari Carmelo,Castella Barbara,Pizzolo Giovanni,Ferrara Felicetto,Chiaretti Sabina,Foà Robin

Publisher

Ferrata Storti Foundation (Haematologica)

Subject

Hematology

Reference17 articles.

1. Leong S, Inglott S, Papaleonidopoulou F. CD1a is rarely expressed in pediatric or adult relapsed/refractory T-ALL: implications for immunotherapy. Blood Adv. 2020; 4(19):4665-4668.

2. Bride KL, Vincent TL, Im S-Y. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood. 2018; 131(9):995-999.

3. Vogiatzi F, Winterberg D, Lenk L. Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia. Blood. 2019; 134(8):713-716.

4. Naik J, Themeli M, de Jong-Korlaar R. CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia. Haematologica. 2019; 104(3):e100-e103.

5. Ofran Y, Ringelstein-Harlev S, Slouzkey I. Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia. Leukemia. 2020; 34(1):293-295.

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The clinical efficacy of a daratumumab-based regimen in relapsed/refractory acute leukemia: a single-center experience;Annals of Hematology;2024-07-24

2. Advances in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia;Blood Reviews;2024-07

3. Naked antibodies and antibody-drug conjugates: targeted therapy for childhood acute lymphoblastic leukemia;Haematologica;2024-05-10

4. Two novel assays demonstrate persistent daratumumab exposure in a pediatric patient with delayed engraftment following allogeneic hematopoietic stem cell transplantation;Cytotherapy;2024-05

5. T-cell Acute Lymphoblastic Leukemia;Advances in Oncology;2024-05